Ubs Group Ag Monte Rosa Therapeutics, Inc. Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
A detailed history of Ubs Group Ag transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 25,333 shares of GLUE stock, worth $215,077. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,333
Previous 23,294
8.75%
Holding current value
$215,077
Previous $87,000
54.02%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding GLUE
# of Institutions
83Shares Held
43.9MCall Options Held
141KPut Options Held
31.2K-
Nea Management Company, LLC Timonium, MD7.69MShares$65.3 Million3.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.6MShares$56 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.79MShares$49.2 Million0.46% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$41.7 Million0.28% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$22.6 Million0.55% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $397M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...